Compare PBH & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | MESO |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 1.8B |
| IPO Year | 2004 | 2005 |
| Metric | PBH | MESO |
|---|---|---|
| Price | $47.81 | $12.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $67.80 | $37.00 |
| AVG Volume (30 Days) | ★ 496.7K | 248.0K |
| Earning Date | 11-05-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $975,777,000.00 | N/A |
| Revenue This Year | $17.03 | $59.17 |
| Revenue Next Year | $6.06 | $59.00 |
| P/E Ratio | $81.10 | ★ N/A |
| Revenue Growth | ★ 36.77 | N/A |
| 52 Week Low | $42.62 | $11.89 |
| 52 Week High | $71.07 | $21.50 |
| Indicator | PBH | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 34.52 |
| Support Level | $47.61 | N/A |
| Resistance Level | $50.00 | $16.06 |
| Average True Range (ATR) | 1.41 | 0.42 |
| MACD | 0.18 | -0.10 |
| Stochastic Oscillator | 46.39 | 15.12 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.